In an exploratory and preliminary clinical test, a team of researchers at Stanford University has obtained “initial evidence” suggesting that a psychoactive compound called ibogaine, when co-administered with magnesium, “could be a powerful therapeutic” to safely treat a variety of psychiatric symptoms, including PTSD, major depression and anxiety, and suicidality, all of which may e

A new medicine for treating schizophrenia—one that appears to help reduce both positive and negative symptoms of the illness—has passed a first hurdle in phase 3 clinical testing. Phase 3 is often pivotal in deciding whether a medicine is effective and safe enough to obtain FDA approval.  

In a new paper, researchers have reported results of the largest double-blind, randomized clinical trial to date comparing the effectiveness and safety of two important therapies for severe and treatment-resistant depression: electroconvulsive therapy (ECT) and magnetic seizure therapy (MST). Both were highly effective, although they differed in some potentially important respects.